Laboratory prediction of clinical chemotherapeutic drug resistance: a working model exemplified by acute leukaemia (Q40920408)

24 September 2017

1 reference

title

Laboratory prediction of clinical chemotherapeutic drug resistance: a working model exemplified by acute leukaemia (English)

1 reference

24 September 2017

1 reference

1 reference

Larsson R

1 reference

24 September 2017

Nygren P

1 reference

24 September 2017

publication date

1 January 1993

1 reference

European Journal of Cancer

24 September 2017

published in

1 reference

24 September 2017

volume

29A

1 reference

24 September 2017

1 reference

24 September 2017

page(s)

1208-1212

1 reference

Cellular and pharmacologic aspects of drug resistance in acute myeloid leukemia

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980316-8

7 January 2021

Role of the Glutathione Redox Cycle in Acquired and de Novo Multidrug Resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980316-8

7 January 2021

The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980316-8

7 January 2021

Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980316-8

7 January 2021

Chemosensitivity testing of fresh human leukemia cells using both a dye exclusion assay and a tetrazolium dye (MTT) assay

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980316-8

7 January 2021

Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980316-8

7 January 2021

Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980316-8

7 January 2021

An in vitro chemosensitivity test for the screening of anti-cancer drugs in childhood leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980316-8

7 January 2021

Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980316-8

7 January 2021

Clinical pharmacokinetics-pharmacodynamics of anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980316-8

7 January 2021

Disposition of epirubicin and metabolites with repeated courses to cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980316-8

7 January 2021

Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980316-8

7 January 2021

Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980316-8

7 January 2021

Assessment of c-myc expression in individual leukemic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980316-8

7 January 2021

A critical appraisal of the predictive value of in vitro chemosensitivity assays.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980316-8

7 January 2021

PET scanning in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980316-8

7 January 2021

10.1016/S0959-8049(05)80316-8

Identifiers

DOI

1 reference

24 September 2017

1 reference